TMO — Thermo Fisher Scientific Inc.
Healthcare · ETF XLV · as of 2026-09-18
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instrum...
Price & today
| Stock today | -1.04% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -0.79% |
Sector correlation
| 20-day correlation with XLV | 0.29 |
| 60-day correlation with XLV | 0.44 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $632.79 |
| 20 EMA | $621.61 |
| 50 EMA | $591.71 |
| EMA stack | BULLISH |
| RSI(14) | 67.6 |
| 52-week high distance | +1.16% |
| 52-week low distance | +69.01% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (11d) |
| Sector rank | #425 |
| Next earnings | 2026-10-20 (BMO, 31d) |
MarketSmith metrics - our compute
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
Company data - context read, not entry inputs
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Oct-24 | 5.28 | -7% | 10,598.0 | +0% |
| Jan-25 | 6.10 | +8% | 11,395.0 | +5% |
| Apr-25 | 5.15 | +1% | 10,364.0 | +0% |
| Jul-25 | 5.36 | +0% | 10,855.0 | +3% |
| Oct-25 | 5.79 | +10% | 11,122.0 | +5% |
| Jan-26 | 6.57 | +8% | 12,215.0 | +7% |
| Apr-26 | 5.44 | +6% | 11,005.0 | +6% |
| Jul-26 | 6.03 | +12% | 11,994.0 | +10% |
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 17 + Riyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia's Commitment to Lead the Future of Biotechnology GlobeNewswire Inc.
- Sep 17 · Buy 3 Needham Mutual Funds for Long-Term Gains Zacks Investment Research
- Sep 15 + Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable Biomanufacturing GlobeNewswire Inc.
- Sep 08 + Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus Zacks Investment Research
- Sep 07 · Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030 GlobeNewswire Inc.
- Sep 04 + Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share GlobeNewswire Inc.
- Sep 01 + TMO Stock Could Gain Following the Launch of EMPAD G2 Detector Zacks Investment Research
- Aug 31 + Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035 GlobeNewswire Inc.